Drug Eluting Stents (DES) Market 2021–2027: Latest Trends, Market Size, Top Impacting Factors and Business Development Strategies By Abbott Vascular, Advantec Vascular, B.Braun Melsengen AG, Biosensors, Biotronik, Blue Medical, Boston Scientific, DISA V

A drug-eluting stent (DES) is usually placed within the peripheral or coronary artery during an angioplasty procedure.

Increasing prevalence of coronary artery disease and other cardiovascular diseases is expected to boost growth of Asia Pacific drug-eluting stents market over the forecast period. For instance, according to the study ‘Divergent trends in ischaemic heart disease and stroke mortality in India from 2000 to 2015: a nationally representative mortality study’, published in the journal Lancet in August 2018, heart ailments caused more than 2.1 million deaths in India in 2015 at all ages. Moreover, 0.9 million deaths were caused by coronary heart disease and 0.4 million by stroke.

Get Sample Report- https://www.stratagemmarketinsights.com/sample/9424

DES are superior to bare metal stents in saphenous vein grafts, which is also expected to boost their adoption, thereby propelling growth of the market. DES is preferred to bare metal stent for elective and emergency percutaneous coronary intervention, owing to the ability of DES to reduce major adverse cardiac events in native coronary artery disease.

However, availability of alternatives such as medical therapy and coronary artery bypass grafting is expected to hinder growth of the market. Moreover, use of DES may lead to clot thrombosis formation, which is also expected to limit adopting of DESs.

The demand for biodegradable polymer DES is increasing compared to second-generation polymer drug-eluting. Biodegradable polymer DES offers long-term outcomes compared with a second-generation durable polymer drug-eluting stent during percutaneous coronary intervention for the treatment of patients with acute myocardial infarction.

Major players in the market are focused on conducting clinical trials to expand their product portfolio. For instance, in November 2019, Boston Scientific announced positive data for Eluvia Drug-Eluting Vascular Stent for the treatment of femoropopliteal disease.

In July 2019, SINOMED completed enrollment in the PIONEER III randomized, controlled clinical trial to assess the safety and effectiveness of the BuMA Supreme DES in order to obtain key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System.

Key Takeaways:

Increasing prevalence of cardiovascular diseases is expected to augment growth of Asia Pacific drug-eluting stents market over the forecast period
Use of DES may lead to clot thrombosis formation, which is expected to limit growth of the market
Major players operating in Asia Pacific drug-eluting stents market include Abbott Vascular, Advantec Vascular, B. Braun Melsengen AG, Biosensors, Biotronik, Blue Medical, Boston Scientific, DISA Vascular, Essen, Medtronic Vascular, MicroPort Medical, MIV Therapeutics, Orbusneich, Promed Medical, Relisys Medical, Reva Medical, Sahajanand, Sino Medical, Sorin, and Terumo Medical

Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Drug Eluting Stents (DES) for these regions, from 2014 to 2025 (forecast), including
➟ China
➟ Japan
➟ South Korea
➟ Taiwan
➟ India
➟ Southeast Asia
➟ Australia

Asia-Pacific Drug Eluting Stents (DES) market competition by top manufacturers/players, with Drug Eluting Stents (DES) sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

➟ Abbott Vascular
➟ Advantec Vascular
➟ B.Braun Melsengen AG
➟ Biosensors
➟ Biotronik
➟ Blue Medical
➟ Boston Scientific
➟ DISA Vascular
➟ Essen
➟ Medtronic Vascular
➟ MicroPort Medical
➟ MIV Therapeutics
➟ Orbusneich
➟ Promed Medical
➟ Relisys Medical
➟ Reva Medical
➟ Sahajanand
➟ Sino Medical
➟ Sorin
➟ Terumo Medical

Buy Now- https://www.stratagemmarketinsights.com/cart/9424

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into

➟ Cobalt-chromium alloy Stents
➟ Magnesium alloy Stents
➟ Tyrosine polycarbonate Stents
➟ Nitinol Stents
➟ Platinum chromium alloy Stents
➟ Stainless steel Stents
➟ Other Materials

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of Drug Eluting Stents (DES) for each application, including

➟ Coronary Heart Disease
➟ Clinical

▣ Note: If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us:
Mr. Shah
Stratagem Market Insights
Tel: US +1 415 871 0703 / JAPAN +81-50-5539-1737
Email: sales@stratagemmarketinsights.com
Explore By- SK

About Stratagem Market Insights:

Stratagem Market Insights is a management consulting organization providing market intelligence and consulting services worldwide. We bring the expertise of consultants with an cumulative industry experience of more than 70 years. The firm has been providing quantified B2B research and currently offers services to over 350+ customers worldwide. Our reports cover various end-use industries such as Aerospace and Defense, Agriculture, Food and Beverages, Automotive, Chemicals and Materials, Consumer Goods and Retail, Electronics, Energy, Mining, and Utilities, Pharmaceuticals, Manufacturing and Construction, Services, and Healthcare, and ICT.

This release was published on openPR.